Checkpoint Therapeutics (CKPT) Price & Analysis

Compare

1,968 Followers

CKPT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.80 - $4.50

Previous CloseN/A

Volume626.20K

Average Volume (3M)N/A

Market Cap

$370.71M

Enterprise Value$208.65M

Total Cash (Recent Filing)$4.93M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.52

Next Earnings

Aug 07, 2025

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding44,620,000

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.56

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit24.56

Enterprise Value/Ebitda-3.70

Forecast

1Y Price Target

$4.45

Price Target Upside4.46% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

AcquisitionCheckpoint is being acquired by Sun Pharmaceuticals at a significant premium, representing a major achievement for the company.

FDA ApprovalCheckpoint's drug, cosibelimab-ipdl, received FDA approval as the first and only PD-L1 blocking antibody for certain cSCC patients, marking a significant advancement.

Strategic TransactionsThe approval of UNLOXCYT is expected to unlock substantial value and increase the price target from $4 to $7.

Bears Say

Capital RaisingThere is less than a 5% likelihood that the company will raise the capital required to commercialize UNLOXCYT itself.

Resource CommitmentManufacturing, marketing, and sales of cosibelimab would require significant commitment of resources that has yet to emerge.

Checkpoint Therapeutics News

Checkpoint Therapeutics Completes Merger with Sun Pharma Subsidiary

Checkpoint Therapeutics ( ($CKPT) ) has provided an announcement. Checkpoint Therapeutics, Inc. announced the completion of a merger...

2M ago

CKPT

Checkpoint Therapeutics Approves Merger with Sun Pharma

The latest update is out from Checkpoint Therapeutics ( ($CKPT) ). On May 28, 2025, Checkpoint Therapeutics held...

2M ago

CKPT

Checkpoint Therapeutics Reports Q1 2025 Financials and Updates

Checkpoint Therapeutics ( ($CKPT) ) has released its Q1 earnings. Here is a breakdown of the information Checkpoint...

3M ago

CKPT

Checkpoint Therapeutics Merger Awaits Stockholder Vote

An announcement from Checkpoint Therapeutics ( ($CKPT) ) is now available. On March 9, 2025, Checkpoint Therapeutics entered...

3M ago

CKPT

Checkpoint Therapeutics Reports 2024 Financial Results and Merger

Checkpoint Therapeutics ( ($CKPT) ) has released its Q4 earnings. Here is a breakdown of the information Checkpoint...

4M ago

CKPT

Checkpoint Therapeutics reports FY24 EPS ($1.42) vs ($3.17) last year

Reports FY24 revenue $41k vs $103k last year Published first on TheFly – the ultimate source for real-time,...

4M ago

CKPT

Beam, Unity, Checkpoint, Inuvo, Ocular: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($BEAM) ), ( ($U) ), ( ($CKPT) ), ( ($INUV)...

5M ago

BEAM

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

5M ago

AEON

APRE

Fortress Biotech price target raised to $16 from $15 at Roth MKM

Roth MKM raised the firm’s price target on Fortress Biotech (FBIO) to $16 from $15 and keeps a...

5M ago

CKPT

FBIO

Checkpoint Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Checkpoint Therapeutics (CKPT) to Neutral from Buy with a price target of $4.10, down from...

5M ago

CKPT

3 Penny Stocks to Watch Now, 3/11/25

Sharps Technology, Checkpoint Therapeutics, and Sonoma Pharmaceuticals are the 3 Penny Stocks to watch on March 11, 2025, based on TipRanks’...

5M ago

CKPT

SNOA

Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma

Shares of Checkpoint Therapeutics (CKPT) have jumped $1.59, or 64%, to $4.06 in Monday morning trading after the...

5M ago

CKPT

FBIO

Checkpoint Therapeutics downgraded to Hold from Buy at Lake Street

Lake Street downgraded Checkpoint Therapeutics (CKPT) to Hold from Buy with a price target of $4.10, down from...

5M ago

CKPT

Unusually active option classes on open March 10th

Unusual total active option classes on open include: Biogen (BIIB), Checkpoint Therapeutics (CKPT), Veren Inc. (VRN), Redfin (RDFN),...

5M ago

DOW

KHC

CKPT FAQ

What was Checkpoint Therapeutics’s price range in the past 12 months?

Checkpoint Therapeutics lowest stock price was $1.80 and its highest was $4.50 in the past 12 months.

What is Checkpoint Therapeutics’s market cap?

Checkpoint Therapeutics’s market cap is $370.71M.

When is Checkpoint Therapeutics’s upcoming earnings report date?

Checkpoint Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is yesterday.

How were Checkpoint Therapeutics’s earnings last quarter?

Currently, no data Available

Is Checkpoint Therapeutics overvalued?

According to Wall Street analysts Checkpoint Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Checkpoint Therapeutics pay dividends?

Checkpoint Therapeutics does not currently pay dividends.

What is Checkpoint Therapeutics’s EPS estimate?

Checkpoint Therapeutics’s EPS estimate is -0.02.

How many shares outstanding does Checkpoint Therapeutics have?

Checkpoint Therapeutics has 44,620,000 shares outstanding.

What happened to Checkpoint Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Checkpoint Therapeutics?

Currently, no hedge funds are holding shares in CKPT

Checkpoint Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-1869.55%

Trailing 12-Months

Asset Growth

185.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. (CKPT) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of immuno-oncology and targeted therapy treatments for patients with solid tumor cancers. The company focuses on developing a robust pipeline of novel combination therapies aimed at treating various cancer indications. Checkpoint Therapeutics' lead product candidates include cosibelimab, an anti-PD-L1 antibody, and CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor.

Checkpoint Therapeutics (CKPT) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

CKPT Stock 12 Month Forecast

Average Price Target

$4.45

▲(4.46% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","1.25":"$1.25","2.5":"$2.5","3.75":"$3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.26,4.3015384615384615,4.343076923076923,4.384615384615384,4.426153846153846,4.467692307692308,4.509230769230769,4.55076923076923,4.592307692307692,4.633846153846154,4.6753846153846155,4.716923076923076,4.758461538461538,{"y":4.8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.26,4.274615384615385,4.289230769230769,4.303846153846154,4.318461538461539,4.333076923076923,4.3476923076923075,4.362307692307692,4.376923076923077,4.391538461538461,4.406153846153846,4.420769230769231,4.435384615384615,{"y":4.45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.26,4.247692307692308,4.235384615384615,4.223076923076923,4.21076923076923,4.1984615384615385,4.186153846153846,4.173846153846154,4.161538461538461,4.149230769230769,4.136923076923076,4.124615384615384,4.1123076923076916,{"y":4.1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.74,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Similar Stocks

ETON

Eton Pharmaceuticals

―

PHAT

Phathom Pharmaceuticals

―

AMLX

Amylyx Pharmaceuticals Inc

―

ZBIO